281 related articles for article (PubMed ID: 21908620)
1. Activation of extracellular transglutaminase 2 by thioredoxin.
Jin X; Stamnaes J; Klöck C; DiRaimondo TR; Sollid LM; Khosla C
J Biol Chem; 2011 Oct; 286(43):37866-73. PubMed ID: 21908620
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
[TBL] [Abstract][Full Text] [Related]
3. Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2.
Yi MC; Melkonian AV; Ousey JA; Khosla C
J Biol Chem; 2018 Feb; 293(8):2640-2649. PubMed ID: 29305423
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.
Antonella Nadalutti C; Korponay-Szabo IR; Kaukinen K; Wang Z; Griffin M; Mäki M; Lindfors K
PLoS One; 2013; 8(10):e77277. PubMed ID: 24130874
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
DiRaimondo TR; Plugis NM; Jin X; Khosla C
J Med Chem; 2013 Feb; 56(3):1301-10. PubMed ID: 23327656
[TBL] [Abstract][Full Text] [Related]
6. Redox regulation of transglutaminase 2 activity.
Stamnaes J; Pinkas DM; Fleckenstein B; Khosla C; Sollid LM
J Biol Chem; 2010 Aug; 285(33):25402-9. PubMed ID: 20547769
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Measurement of Redox-Regulated TG2 Activity.
Melkonian AV; Weng N; Palanski BA; Khosla C
Methods Mol Biol; 2019; 1967():263-274. PubMed ID: 31069776
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy.
Diraimondo TR; Klöck C; Khosla C
J Pharmacol Exp Ther; 2012 Apr; 341(1):104-14. PubMed ID: 22228808
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
10. Unexpected role of surface transglutaminase type II in celiac disease.
Maiuri L; Ciacci C; Ricciardelli I; Vacca L; Raia V; Rispo A; Griffin M; Issekutz T; Quaratino S; Londei M
Gastroenterology; 2005 Nov; 129(5):1400-13. PubMed ID: 16285941
[TBL] [Abstract][Full Text] [Related]
11. Activation and inhibition of transglutaminase 2 in mice.
Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
[TBL] [Abstract][Full Text] [Related]
12. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 expression is enhanced synergistically by interferon-γ and tumour necrosis factor-α in human small intestine.
Bayardo M; Punzi F; Bondar C; Chopita N; Chirdo F
Clin Exp Immunol; 2012 Apr; 168(1):95-104. PubMed ID: 22385244
[TBL] [Abstract][Full Text] [Related]
14. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
[TBL] [Abstract][Full Text] [Related]
15. Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange.
Iversen R; Mysling S; Hnida K; Jørgensen TJ; Sollid LM
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17146-51. PubMed ID: 25404341
[TBL] [Abstract][Full Text] [Related]
16. Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an in Vitro Model of Celiac Disease.
Attarwala H; Clausen V; Chaturvedi P; Amiji MM
Mol Pharm; 2017 Sep; 14(9):3036-3044. PubMed ID: 28737923
[TBL] [Abstract][Full Text] [Related]
17. The redox state of transglutaminase 2 controls arterial remodeling.
van den Akker J; VanBavel E; van Geel R; Matlung HL; Guvenc Tuna B; Janssen GM; van Veelen PA; Boelens WC; De Mey JG; Bakker EN
PLoS One; 2011; 6(8):e23067. PubMed ID: 21901120
[TBL] [Abstract][Full Text] [Related]
18. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
19. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 4 is inactivated via selective disulfide-bond reduction by extracellular thioredoxin.
Plugis NM; Weng N; Zhao Q; Palanski BA; Maecker HT; Habtezion A; Khosla C
Proc Natl Acad Sci U S A; 2018 Aug; 115(35):8781-8786. PubMed ID: 30104382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
